Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.77 |
| ▸ | ITGAV | P06756 | 17/20 | 0.77 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.77 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212733 | 0.89 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL12010936 | 0.89 | ITGB3 (0.76) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL6418885 | 0.89 | ITGB3 (0.78) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL6418879 | 0.89 | ITGB3 (0.78) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL538331 | 0.87 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL5360850 | 0.87 | ITGB3 (0.73) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL244675 | 0.87 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL29571589 | 0.87 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL29899937 | 0.87 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL6418626 | 0.84 | ITGB3 (0.67) | ITGB3ITGAVITGA2BITGB6ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-03-11 | — | — | US | disclosed |
| EP-1443963-B1 | ANTIBODY TARGETING COMPOUNDS | SCRIPPS RESEARCH INST (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20130171074-A1 | TARGETING COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-07-04 | — | — | US | disclosed |
| EP-1446418-B1 | INTEGRIN TARGETING COMPOUNDS | SCRIPPS RESEARCH INST (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2428226-A1 | Antibody targeting compounds | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2003034995-A2 | INTEGRIN TARGETING COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171074-A1 | TARGETING COMPOUNDS | CD47, CD22, FCGR2A | ITGB3 446/4885ITGAV 169/4885ITGA2B 244/4885 |
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | ITGB3 4/4885ITGAV 1/4885ITGA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.